Bank of New York Mellon’s Trillium Therapeutics Inc. TRIL Stock Holding History

Bank of New York Mellon’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-304,203	Closed	-$5.34M	–	4707
2021 Q3	$5.34M	Buy	304,203 +36,301	+14%	+$424K	﹤0.01%	2452
2021 Q2	$2.6M	Buy	+267,902	New	+$2.52M	﹤0.01%	2832
2016 Q1	–	Sell	-10,946	Closed	-$138K	–	4321
2015 Q4	$138K	Buy	10,946 +143	+1%	+$1.99K	﹤0.01%	3980
2015 Q3	$141K	Buy	+10,803	New	+$199K	﹤0.01%	4018

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $371B AUM 64.6% 1-Year Est. Return

Bank of New York Mellon's TRIL Position: Q4 2021 in Review

Bank of New York Mellon sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 304,203 shares — an estimated $5.34M sold.

Bank of New York Mellon first reported a position in TRIL in Q3 2015 and held it in 4 quarters. The position peaked at $5.34M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Bank of New York Mellon reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Bank of New York Mellon sold 304,203 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $5.34M.
Bank of New York Mellon first reported a position in Trillium Therapeutics Inc. in Q3 2015 and held it in 4 quarters.
Bank of New York Mellon's Trillium Therapeutics Inc. position peaked at $5.34M in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Bank of New York Mellon's 13F filing for Q4 2021, filed 11 Feb 2022.